In addition to the well-recognized immune checkpoints PD-1/PD-L1 and CTLA-4, more and more studies have found that tumor immune escape and drug resistance may be related to other less-appreciated immune checkpoints (Andrews et al., 2019). This evidence concerns the gene CTLA4 and neoplasm.